日本語 / English
DefiniGEN was founded in April 2013 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK.
The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.
DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and in addition has in-licensed the Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.
iPS, Regenerative medicine, Differentiation, Hepatocyte, Pancreatic beta cells, Intestinal Organoids, Disease modelling, Drug Discovery
Production of iPS-differentiated cells (cryo-preserved)
Custom gene-editing to derive specific disease modells
Custom project (iPS-reprogramming & differentiation)
Relationship to Biospire
Business development support to the global market.
Babraham Research Campus